< Back to previous page

Patent

Method for the treatment of dravet syndrome

A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Patent Publication Number: US10478441
Year filing: 2019
Year approval: 2019
Year publication: 2019
Status: Assigned
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven, Associatie Universiteit & Hogescholen Antwerpen